Product Information
DOLOBID 250 MG TABLET is a generic product labeled by INA Pharmaceutics Inc, priced at $20.4233 per EA under NDC 74157000960. Its NADAC has been published 10 times since Sep 17, 2025.
FDA first approved this application on Mar 8, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Diflunisal market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/1
Manufacturer
INA Pharmaceutics IncNDC
74157000960
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
11/18/2026
Active Ingredients
DIFLUNISALApproval Type
Generic (ANDA)
FDA Application
ANDA202845FDA Approved
3/8/2012
TE Code
AB
On Market Since
8/19/2024
Pharmacological Classes
Price Statistics
The NADAC for DOLOBID 250 MG TABLET has been published 10 times since Sep 17, 2025, and over the history we have for it it has declined 10.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $20.4233 per EA |
|---|---|
| All-time high | $22.8653 (Oct 15, 2025) |
| All-time low | $20.4233 (Nov 18, 2026) |
| 52-week high | $20.6317 |
| 52-week low | $20.4233 |
| Median price | $21.7485 |
| Average price | $21.7276 |
| Largest weekly change | -9.8% (Oct 21, 2026) |
| Weeks tracked | 10 |
| Tracking since | Sep 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Diflunisal market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
INA Pharmaceutics Inc manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Diflunisal market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOLOBID 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DOLOBID 250 MG TABLET, manufactured by INA Pharmaceutics Inc, is $20.4233 per EA (NDC 74157000960), effective Nov 18, 2026.
How has the price of DOLOBID 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for DOLOBID 250 MG TABLET has declined 10.7%. It has been tracked across 10 weekly CMS publications since Sep 17, 2025.
What are the highest and lowest recorded NADAC prices for DOLOBID 250 MG TABLET?
Since Sep 17, 2025, the NADAC for DOLOBID 250 MG TABLET has ranged from a low of $20.4233 (Nov 18, 2026) to a high of $22.8653 (Oct 15, 2025), with a median of $21.7485 per EA.
Are there cheaper alternatives to DOLOBID 250 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of DOLOBID 250 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOLOBID 250 MG TABLET?
DOLOBID 250 MG TABLET (NDC 74157000960) is labeled by INA Pharmaceutics Inc, and CMS classifies it as a generic product.